CL2017000576A1 - Inhibidores de mk2 y sus usos - Google Patents

Inhibidores de mk2 y sus usos

Info

Publication number
CL2017000576A1
CL2017000576A1 CL2017000576A CL2017000576A CL2017000576A1 CL 2017000576 A1 CL2017000576 A1 CL 2017000576A1 CL 2017000576 A CL2017000576 A CL 2017000576A CL 2017000576 A CL2017000576 A CL 2017000576A CL 2017000576 A1 CL2017000576 A1 CL 2017000576A1
Authority
CL
Chile
Prior art keywords
inhibitors
compositions
methods
same
provides compounds
Prior art date
Application number
CL2017000576A
Other languages
English (en)
Inventor
Deqiang Niu
Russell C Petter
Juswinder Singh
Joseph John Mcdonald
Matthew David Alexander
Claudio Chauaqui
John Malona
Yike Ni
Chitari Pabba
Original Assignee
Celgene Car Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Car Llc filed Critical Celgene Car Llc
Publication of CL2017000576A1 publication Critical patent/CL2017000576A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA COMPUESTOS, COMPOSICIONES DE LOS MISMOS Y MÉTODOS PARA UTILIZARLOS.</p>
CL2017000576A 2014-09-17 2017-03-09 Inhibidores de mk2 y sus usos CL2017000576A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US201562199927P 2015-07-31 2015-07-31

Publications (1)

Publication Number Publication Date
CL2017000576A1 true CL2017000576A1 (es) 2017-12-01

Family

ID=55454109

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000576A CL2017000576A1 (es) 2014-09-17 2017-03-09 Inhibidores de mk2 y sus usos

Country Status (30)

Country Link
US (5) US9458175B2 (es)
EP (2) EP3193611B1 (es)
JP (3) JP6556225B2 (es)
KR (1) KR102457848B1 (es)
CN (1) CN106998692B (es)
AU (1) AU2015317741B2 (es)
BR (1) BR112017005266B1 (es)
CA (1) CA2961607C (es)
CL (1) CL2017000576A1 (es)
CO (1) CO2017003279A2 (es)
CY (1) CY1124215T1 (es)
DK (1) DK3193611T3 (es)
EA (1) EA037299B1 (es)
EC (1) ECSP17023281A (es)
ES (1) ES2874561T3 (es)
HR (1) HRP20210529T1 (es)
HU (1) HUE054347T2 (es)
IL (1) IL251051B (es)
LT (1) LT3193611T (es)
MA (1) MA40534B1 (es)
MX (2) MX2017003359A (es)
NZ (1) NZ730603A (es)
PL (1) PL3193611T3 (es)
PT (1) PT3193611T (es)
RS (1) RS62017B1 (es)
SA (1) SA517381115B1 (es)
SG (2) SG10201902326XA (es)
SI (1) SI3193611T1 (es)
TW (1) TWI744217B (es)
WO (1) WO2016044463A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968339A4 (en) 2013-03-15 2017-02-15 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
CN110678178B (zh) * 2017-03-16 2023-10-03 百时美施贵宝公司 Mk2抑制剂的形式和组合物
WO2018170200A1 (en) * 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
US10894796B2 (en) 2017-03-16 2021-01-19 Celgene Car Llc MK2 inhibitors, synthesis thereof, and intermediates thereto
EP3596084A4 (en) * 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4.5] THIENO [3,2-F] QUINOLINE-8-ON COMPOUNDS AND USES THEREOF
EP3596085A4 (en) * 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
KR20220041042A (ko) * 2019-05-17 2022-03-31 셀젠 카르 엘엘씨 Mk2-매개 장애를 치료하는 방법
WO2021163633A1 (en) * 2020-02-14 2021-08-19 Salk Institute For Biological Studies Mono and combination therapies with ulk1/2 inhibitors
EP4114411A4 (en) * 2020-03-02 2024-04-24 Washington University St Louis COMPOSITIONS AND METHODS FOR THE TREATMENT OF PANCREATIC CANCER
KR20230044446A (ko) * 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법
EP4079855A1 (en) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound and method for the prophylaxis and treatment of leukemia
WO2023025298A1 (zh) * 2021-08-27 2023-03-02 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
KR20040068613A (ko) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
EP1572693A1 (en) 2002-12-20 2005-09-14 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
CA2536954C (en) 2003-08-29 2012-11-27 Exelixis, Inc. C-kit modulators and methods of use
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
ES2776973T3 (es) 2005-02-04 2020-08-03 Firmenich Incorporated Compuestos que comprenden restos de heteroarilo unidos y su uso como nuevos modificadores del sabor umami, saborizantes y potenciadores del sabor para composiciones comestibles
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2693904A1 (en) 2007-07-16 2009-01-22 Novartis Ag Heterocyclic compounds useful as mk2 inhibitors
JP2011500727A (ja) 2007-10-22 2011-01-06 シェーリング コーポレイション Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用
KR101892989B1 (ko) 2008-06-27 2018-08-30 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
WO2011153553A2 (en) * 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2511273B8 (en) * 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
CN104136576B (zh) 2012-02-22 2020-10-16 默克专利股份有限公司 液晶介质
WO2013146963A1 (ja) * 2012-03-28 2013-10-03 武田薬品工業株式会社 複素環化合物
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
US9085586B2 (en) * 2012-07-11 2015-07-21 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
PE20151253A1 (es) * 2012-09-24 2015-10-04 Claremont Speede Metodo y sistema de acceso a datos y eliminacion de datos controlados por emisor movil
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
EP2968339A4 (en) * 2013-03-15 2017-02-15 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
WO2015050957A2 (en) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Treatments for systemic lupus erythematosus
US10512651B2 (en) 2014-08-25 2019-12-24 Stc.Unm Inhibition of MK2 in the treatment of cancer
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
AU2016205125A1 (en) 2015-01-08 2017-07-13 Moerae Matrix, Inc. Formulation of MK2 inhibitor peptides
CN110678178B (zh) 2017-03-16 2023-10-03 百时美施贵宝公司 Mk2抑制剂的形式和组合物
EP3596084A4 (en) 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4.5] THIENO [3,2-F] QUINOLINE-8-ON COMPOUNDS AND USES THEREOF
WO2018170200A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
EP3596085A4 (en) 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
US10894796B2 (en) 2017-03-16 2021-01-19 Celgene Car Llc MK2 inhibitors, synthesis thereof, and intermediates thereto
KR20220041042A (ko) 2019-05-17 2022-03-31 셀젠 카르 엘엘씨 Mk2-매개 장애를 치료하는 방법
KR20230044446A (ko) 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법

Also Published As

Publication number Publication date
US9790235B2 (en) 2017-10-17
AU2015317741A1 (en) 2017-04-20
JP2017529367A (ja) 2017-10-05
CA2961607A1 (en) 2016-03-24
TWI744217B (zh) 2021-11-01
SG11201701861RA (en) 2017-04-27
US11584757B2 (en) 2023-02-21
BR112017005266B1 (pt) 2022-11-01
SA517381115B1 (ar) 2021-03-09
EP3193611B1 (en) 2021-03-24
EA201790380A1 (ru) 2017-08-31
US20190375762A1 (en) 2019-12-12
MX2017003359A (es) 2017-11-22
US20170114073A1 (en) 2017-04-27
US20210053984A1 (en) 2021-02-25
US20160075720A1 (en) 2016-03-17
WO2016044463A3 (en) 2016-09-01
LT3193611T (lt) 2021-08-25
TW201617351A (zh) 2016-05-16
IL251051B (en) 2019-11-28
JP6556225B2 (ja) 2019-08-07
BR112017005266A2 (pt) 2017-12-12
ES2874561T3 (es) 2021-11-05
HRP20210529T1 (hr) 2021-08-06
MX2020005213A (es) 2020-08-20
US9458175B2 (en) 2016-10-04
EP3193611A2 (en) 2017-07-26
WO2016044463A2 (en) 2016-03-24
SG10201902326XA (en) 2019-04-29
CA2961607C (en) 2023-03-28
EA037299B1 (ru) 2021-03-05
CN106998692B (zh) 2020-09-08
KR20170063734A (ko) 2017-06-08
EP3912981A1 (en) 2021-11-24
MA40534A (fr) 2016-03-24
AU2015317741B2 (en) 2020-01-16
EP3193611A4 (en) 2018-02-28
JP2022078315A (ja) 2022-05-24
RS62017B1 (sr) 2021-07-30
NZ730603A (en) 2024-02-23
KR102457848B1 (ko) 2022-10-25
JP2019194236A (ja) 2019-11-07
DK3193611T3 (da) 2021-05-10
CN106998692A (zh) 2017-08-01
US10577380B2 (en) 2020-03-03
ECSP17023281A (es) 2017-06-30
CY1124215T1 (el) 2022-05-27
IL251051A0 (en) 2017-04-30
PL3193611T3 (pl) 2021-10-04
MA40534B1 (fr) 2021-04-30
SI3193611T1 (sl) 2021-08-31
JP7375072B2 (ja) 2023-11-07
US10253040B1 (en) 2019-04-09
HUE054347T2 (hu) 2021-08-30
PT3193611T (pt) 2021-05-28
CO2017003279A2 (es) 2017-09-29

Similar Documents

Publication Publication Date Title
CL2017000576A1 (es) Inhibidores de mk2 y sus usos
CO2018005381A2 (es) Inhibidores éster de acc y usos de los mismos
CR20150462A (es) Inhibidores de erk y sus usos
CO2018005368A2 (es) Inhibidores pirazol de acc y usos de los mismos
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
CL2016001871A1 (es) Anticuerpos humanos para pd-1
CO2017011151A2 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
UY37523A (es) Anticuerpos anti-ox40 y sus usos
ECSP18049420A (es) Composiciones novedosas, usos y métodos para hacerlas
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
CL2016002731A1 (es) Herbicidas de piridazinona
CO2017011152A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx / ca.
CL2017001046A1 (es) Inhibidoes del bromodominio
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
UY37018A (es) Inhibidores bicíclicos de pad4
DK3102555T3 (da) Sammensætninger af forbindelser og anvendelser deraf
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
UY37017A (es) Inhibidores aza-bencimidazol de pad4